MRI-guided clinical 6-MV radiosensitization of glioma using a unique gadolinium-based nanoparticles injection

Nanomedicine (Lond). 2016 Sep;11(18):2405-17. doi: 10.2217/nnm-2016-0203. Epub 2016 Aug 16.


Aim: This study reports the use of gadolinium-based AGuIX nanoparticles (NPs) as a theranostic tool for both image-guided radiation therapy and radiosensitization of brain tumors.

Materials & methods: Pharmacokinetics and regulatory toxicology investigations were performed on rodents. The AGuIX NPs' tumor accumulation was studied by MRI before 6-MV irradiation.

Results: AGuIX NPs exhibited a great safety profile. A single intravenous administration enabled the tumor delineation by MRI with a T1 tumor contrast enhancement up to 24 h, and the tumor volume reduction when combined with a clinical 6-MV radiotherapy.

Conclusion: This study demonstrates the efficacy and the potential of AGuIX NPs for image-guided radiation therapy, promising properties that will be assessed in the upcoming Phase I clinical trial.

Keywords: MRI-guided radiation therapy; clinical 6-MV radiation therapy; radiosensitizing nanoparticles.

MeSH terms

  • Animals
  • Contrast Media / administration & dosage
  • Contrast Media / chemistry
  • Disease Models, Animal
  • Gadolinium / administration & dosage
  • Gadolinium / chemistry
  • Glioma / diagnostic imaging*
  • Glioma / pathology
  • Glioma / radiotherapy*
  • Humans
  • Magnetic Resonance Imaging
  • Metal Nanoparticles / administration & dosage*
  • Metal Nanoparticles / chemistry
  • Radiation-Sensitizing Agents / administration & dosage*
  • Radiation-Sensitizing Agents / chemistry
  • Rats


  • Contrast Media
  • Radiation-Sensitizing Agents
  • Gadolinium